Cardiology
Latest news
1101 articles · 20 / page
Atherectomy Fails to Improve Limb-Based Outcomes in Chronic Limb-Threatening Ischemia: A Critical Analysis of the BEST-CLI Trial
A secondary analysis of the BEST-CLI trial indicates that atherectomy does not improve outcomes for patients with chronic limb-threatening ischemia undergoing endovascular therapy, with some data even suggesting potential harm in technicall
Interleukin-6 Inhibition: A New Frontier in Reducing Residual Cardiovascular and Renal Risk
Recent clinical evidence identifies Interleukin-6 (IL-6) as a critical driver of cardiovascular events. The ZEUS trial and recent LoDoCo2 analyses suggest that targeting IL-6 with ziltivekimab may significantly reduce risk for patients with
Tenecteplase Outperforms Alteplase in Mechanical Heart Valve Thrombosis: Insights from the TENET Trial
The TENET randomized clinical trial reveals that tenecteplase bolus administration achieves significantly higher thrombolytic success rates and shorter hospital stays compared to alteplase infusion for mechanical prosthetic valve thrombosis
Individualized Blood Pressure Targets vs. Standard Care: Insights from the IMPROVE-multi Trial
The IMPROVE-multi trial found that targeting blood pressure based on preoperative nighttime levels did not reduce postoperative complications compared to a standard MAP target of 65 mm Hg in high-risk abdominal surgery patients.
Opportunistic Genomic Screening for Familial Hypercholesterolemia: Does Genetic Feedback Drive Clinical Change?
This randomized clinical trial investigates whether returning opportunistic genomic results for familial hypercholesterolemia to veterans impacts LDL-C levels. While the primary endpoint missed statistical significance, the findings suggest
Hemodynamic Conservation vs. Obliteration: Why the CHIVA Method and Hybrid Innovations are Redefining Venous Insufficiency Care
This clinical analysis explores the CHIVA method’s role in chronic venous insufficiency, highlighting its superior safety profile and low recurrence rates. By synthesizing Cochrane data and emerging technologies like HIFU, it offers a bluep
Finerenone Reduces Albuminuria via Hemodynamic Mechanisms Rather Than Improving Arterial Stiffness: Insights from the FIVE-STAR Trial
The FIVE-STAR trial demonstrates that while finerenone significantly reduces albuminuria in patients with T2D and CKD, it does not improve arterial stiffness (CAVI). These findings suggest that its cardiorenal benefits are primarily driven
Beyond the Arteries: Why Finerenone is a Game-Changer for Diabetic Kidney Disease
The FIVE-STAR trial reveals that finerenone’s cardiorenal benefits stem from reducing internal kidney pressure rather than improving arterial stiffness, offering a new perspective on managing type 2 diabetes and chronic kidney disease.
Bone Metabolism Biomarkers: A New Frontier in Predicting Cardiovascular Risk for Diabetes and Renal Disease
Recent studies demonstrate that biomarkers of bone metabolism, particularly the OPG/TRAIL ratio, are powerful predictors of cardiovascular disease and mortality in patients with type 2 diabetes and chronic kidney disease, offering improved
Large Clonal Hematopoiesis Clones Drive Myocardial Infarction Risk in People With HIV
Data from the REPRIEVE trial indicates that while general clonal hematopoiesis is common in people with HIV, only large clones (VAF ≥10%) significantly elevate the risk for myocardial infarction and revascularization, independent of traditi
Rethinking First-Line Anticoagulation in Older Adults: Real-World Evidence Challenges Conventional AFib Management
A large-scale study of 144,969 Medicare beneficiaries reveals that initial anticoagulant prescriptions for atrial fibrillation may not reduce ischemic stroke risk in patients over 66, while significantly increasing major bleeding hazards, s
Precision Hypertension Management: Haptoglobin Phenotype Predicts Cardiovascular Benefit from Intensive Blood Pressure Control in Type 2 Diabetes
A post-hoc analysis of the ACCORD trial reveals that intensive blood pressure control significantly reduces cardiovascular and stroke risk in haptoglobin 1 allele carriers, but not in those with the Hp2-2 phenotype, suggesting a genotype-dr
Reversing Prediabetes Halves 30-Year Risk of Cardiovascular Death and Heart Failure: New Insights from DPPOS and DaQing
A landmark post-hoc analysis of the DPPOS and DaQing studies reveals that achieving prediabetes remission reduces the risk of cardiovascular death and heart failure hospitalization by approximately 50% over three decades, highlighting a pro
RNAi Targeting of ANGPTL3 with Zodasiran Delivers Substantial LDL-C Lowering in Patients with Homozygous Familial Hypercholesterolaemia
The Phase 2 GATEWAY trial demonstrates that zodasiran, an RNAi therapeutic targeting ANGPTL3, significantly reduces LDL cholesterol in patients with homozygous familial hypercholesterolaemia (HoFH) by approximately 36-40%. The treatment was
Beyond HbA1c: How Diabetes Subtyping Predicts Comorbidities and Mortality Over 14 Years
A landmark Swedish cohort study demonstrates that diabetes subgroups, particularly those characterized by insulin resistance and deficiency, carry significantly higher risks for end-organ damage and cardiovascular mortality than previously
Perioperative Dexmedetomidine Fails to Reduce Major Complications After Cardiac Surgery: Results from the DOCS Trial
The DOCS trial, a multi-center randomized controlled study, found that perioperative dexmedetomidine infusion did not significantly reduce in-hospital mortality or major complications in adults undergoing cardiac surgery with cardiopulmonar
SGLT2 Inhibitors Demonstrate Cardioprotective Benefits Even in Low-Risk Type 2 Diabetes Populations: Insights from a Causal Forest Analysis
A nationwide target trial emulation study reveals that SGLT2 inhibitors provide cardiovascular benefits across a broader range of patients than previously recognized, with benefit more closely tied to individual metabolic traits than tradit
The Hidden Burden of Heart and Brain Health: ASCVD Linked to Significantly Elevated Suicide Risk
A large-scale nationwide study reveals that individuals with atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction and stroke, face a 43% higher risk of suicide. The risk nearly doubles for those suffering from bot
Albiglutide Reduces Cardiovascular Risks in Patients With Type 2 Diabetes Regardless of Atrial Fibrillation Status: Insights From Harmony Outcomes
A sub-analysis of the Harmony Outcomes trial demonstrates that albiglutide consistently reduces major adverse cardiovascular events in Type 2 diabetes patients, irrespective of baseline atrial fibrillation, while showing a trend toward redu
Significant 1-Year Risk of Cardiovascular Events in Cognitive Impairment Highlights Safety Concerns for Anti-Amyloid Therapy
A longitudinal study reveals that over 5% of patients with MCI or dementia develop new indications for anticoagulants or thrombolytics within a year, complicating the use of anti-amyloid monoclonal antibodies due to increased intracranial h
Browse by specialty
Open language-specific specialty feeds and department pages.